Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of diabetes vaccine based on (M)T-DC technology

A diabetes vaccine, T-DC technology, applied in the field of vaccines, can solve problems such as cardiovascular and cerebrovascular damage, vascular cell function decline, blood supply system function decline, etc., to achieve the effect of strengthening, restoring pancreatic function, and preventing relapse or reinfection

Inactive Publication Date: 2018-07-27
西安华洲生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Long-term low-virulence infection will cause the immune system to gradually adapt to this infection. In the case of low immunity, the corresponding immune response cannot be caused against it, resulting in immune tolerance. The body cannot recognize the relevant pathogenic microorganisms, which will lead to pathogenic microorganisms. Long-term persistent infection, causing long-term damage to the body
[0004] This type of infection will cause serious pathological damage to the cardiovascular and cerebrovascular, and the continuous damage of vascular endothelial cells will cause diseases of the vascular system; the destruction of the vascular endothelium will form microthrombi, and the formation of microthrombi will block capillaries, resulting in the slow function of vascular cells. Regression, the progressive damage of blood vessels slowly accumulates, from quantitative deformation to qualitative change, once a breakthrough occurs, the damage to organ function is irreversible; it will lead to a decline in the function of the blood supply system, and damage to blood vessel function will lead to the occurrence of diseases such as diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of diabetes vaccine based on (M)T-DC technology
  • Application of diabetes vaccine based on (M)T-DC technology

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The present invention will be described in detail below in combination with specific embodiments.

[0018] Targeted dendritic cell therapy (Target-Dendritic Cell, T-DC) is to collect autologous peripheral blood mononuclear cells, and add other cytokines in the laboratory to obtain transformed dendritic cells (dendritic cells) with strong antigen-presenting function. , DC). The day before the reinfusion, a specially synthesized single-epitope polyantigen peptide is added, and the DC recognizes and captures the single-epitope polyantigen peptide to obtain mature dendritic cells that are sensitized to the patient's infectious agent virus. Migration and immune activity, go deep into the deep part of the lesion and the surrounding diseased tissue, induce the body to produce a large number of cytotoxic T lymphocytes that have a killing effect on specific antigens, thereby specifically clearing the free virus and intracellular virus in the deep layer of infection and around it...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a diabetes vaccine based on an (M)T-DC technology. The specific single-epitope mutiple antigenic peptide in vitro sensitized dendritic cells are selected to obtain an autologous dendritic cell preparation to realize the combined use with mesenchymal stem cells; blood vessel endothelium injured cells are restored; the vaccine is used as a venous re-transfusion vaccine. The (M)T-DC technology is used for interfering and clearing blood vessel endothelium infection factors; the targeted deep going into local lesion parts can be realized; meanwhile, the mesenchymal stem cell treatment with the multipotential differentiation of a corresponding treatment course is matched for restoring the blood vessel endothelium and dissolving cicatrices, so that the treatment goal is achieved.

Description

technical field [0001] The invention relates to a vaccine, in particular to the application of a diabetes vaccine based on (M)T-DC technology. Background technique [0002] Diabetes mellitus is a metabolic disease characterized by hyperglycemia due to defects in insulin secretion or insulin β-cell action. Sustained high blood sugar and long-term metabolic disorders can lead to damage, dysfunction and failure of tissues and organs throughout the body, especially the eyes, kidneys, cardiovascular and nervous systems. Severe cases can cause acute complications such as dehydration, electrolyte disturbance and acid-base imbalance, ketoacidosis and hyperosmolar coma. Drugs and diet are used in treatment, but it is difficult to achieve the desired effect. [0003] According to research, cytotoxin-associated protein (CagA), vacuolar toxin-associated protein (VacA), urease (Ure), cytomegalovirus (CMV), human papillomavirus (HPV-16), human papillomavirus (HPV- 18), herpes simplex v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/12A61K39/245A61K39/04A61K39/118A61K39/20A61K39/02A61K39/00A61P3/10
CPCA61K39/0005A61K39/002A61K39/0241A61K39/04A61K39/118A61K39/12A61K2039/5158A61K2039/572A61P3/10C12N2710/16133C12N2710/16634C12N2710/20034C12N2770/36234
Inventor 闫小君闫龙
Owner 西安华洲生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products